4. Analyse et interprétation des résultats
4.2 Analyse et commentaires
4.2.10 Avis et ressentis des enseignants
ADH Hormona antidiurética ARN Ácido ribonucleico
ASCO American society of clinical oncology – (sociedade americana de oncologia clínica) CME Compressão medula espinhal
DRI Doença de risco intermediário ECG Electrocardiograma
HAM Hipercalcemia associada a malignidade Igs Imunoglobulinas IM Intramuscular IV Intravenoso LB Linfoma de burkitt LCR Líquido céfaloraquidiano LDH Lactato desidrogenase
LDL Lipoproteínas de baixa densidade LH Linfoma de Hodgkin
LLA Leucemia linfoblástica aguda LMA Leucemia mieloide aguda LMC Leucemia mielóide crónica LNH Linfoma não Hodgkin mEq/L Miliequivalentes por litro mmol/L Mili mol por litro
MW Macroglobulinemia de Valdenstrom
NSCLC Carcinoma não pequenas células do pulmão PIC Pressão intracraniana
PTH Hormona paratiróideia
PTHrP Proteína de libertação da hormona paratiróideia RM Ressonância magnética
Rx Raio x
SC Subcutânea
SCLC Carcinoma pequenas células do pulmão SHV Síndrome da hiperviscosidade
SIADH Secreção inapropriada da hormona antidiurética SLT Sindrome de lise tumoral
SVCS Sindrome da veia cava superior TC Tomografia computorizada UI Unidade internacional VCS Veia cava superior
REFERÊNCIAS
1. Susan JT. Recognition and Treatment of Oncologic Emergencies. Journal of infusion Nursing 2002; Vol. 25, No. 3. 2. Cervantes A. & Chirivella I. Annals of
oncology 15 (Supplement 4): iv299- iv306, 2004.
3. Kattlove H, Winn RJ. Ongoing care of patients after primary treatment for their cancer [Published correction appears in CA Cancer J Clin 2003;53:315]. CA Cancer J Clin 2003;54:172-96.
4. Halfdanarson TR, Hogan WJ, Moyni- han TJ. Oncologic Emergencies: Diag- nosis and Treatment. Mayo Clin Proc June 2006;81(6):835-48.
5. Abeloff MD. Hypercalcemia. Abeloffs´s clinical oncology. 4th edition. Philadel- phia: Churchil Livingston;2004.
6. Yeung SJ, Escalante CP, et al. Oncolo- gic emergencies. In Kufe DW (ed.): Holand-Frei Cancer Medicine, 6th edition. Hamilton, Canada: BC Decker 2003;2659–80.
7. Qanadi SD, Mesurolle B, Sissakian JF et al. Implanted central venous cathe- ter-related acute superior vena cava syndrome: management by metallic stent and endovascular repositioning of the catheter tip. Eur Radiol 2000;10:1329–31.
8. Deepty B, et al. Oncologic Emergen- cies. Crit Care Clin 26 (2010);181-205. 9. Stewart AF. Clinical Practice. Hiper-
calcemia associated with cancer. N Eng J Med 2005; 352(4):373-9.
10. Horwitz MJ, Tedesco MB, Sereika SM et al. Direct comparison of sustained infusion of human parathyroid hormo- ne-related protein–(1-36) [hPTHrP-(1- 36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihidroxivitamin D concentrations and fraccional calcium excretion in healthy human volunteers. J Clin Endocrinol Metab 2003;88(4):1603-9.
11. Nussbaum SR, Gaz RD, Arnold A. Hipercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearranjement of the gene for parathyroide hormone. N Eng J Med 1990;323(19):1324-8.
12. Garrett IR, Durie BG, Nedwin GE, et al. Production of lymphotoxin, a bone-re- sorbing cytokine, by cultured human myeloma cells. N Engl J Med 1987;317:526-32.
13. Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1- alpha is a potential osteoclast stimula- tory factor in multiple myeloma. Blood 2000;96:671-5.
14. Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hyper- calcemia in Hodgkin’s disease and non- Hodgkin’s lymphomas. Blood 1993;82:1383-94.
15. Porte H, Metois D, Finzi L et al. Su- perior vena cava syndrome of malig- nant origin. Which surgical procedure for which diagnosis? Eur J Cardiothorac Surg 2000;17:384-8.
16. Liu G, Crump M, Gross PE et al. Pros- pective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tampo- nade. J Clin Oncol 1996;14:3141-7. 17. Horwitz M, Stewart AF. Hipercalcemia
associated with malignancy. In: favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. 6 edithion. Washington DC: American Society for Bone and Mineral Research 2006;195-9.
18. Roodman G. Mechanisms of bone lesions in multiple myeloma and lym- phoma. Cancer 1997;80(Suppl 8):1557- 63.
19. Deftos LJ. Hypercalcemia in malignant and inflammatory diseases. Endocrinol Metab Clin North Am. 2002;31:141-58.
20. Bushinsky DA, Monk RD. Electrolyte quintet: calcium [published correction appears in Lancet. 2002;359:266]. Lancet 1998;352:306-11.
21. Ratcliffe, WA, Hutchesson, AC, Bun- dred, NJ, Ratcliffe, JG. Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia. Lancet 1992; 339:164.
22. Hutchesson AC, Bundred NJ, Ratcliffe WA. Survival in hypercalcaemic pa- tients with cancer and co-existing pri- mary hyperparathyroidism. Post graded Med J 1995;71(831):28-31.
23. Pecherstorfer M, Schilling T, Blind E, et al. Parathyroid hormone related protein and life expectancy in hypercalcemic cancer patients. J Clin Endocrinol Me- tab 1994;78:1268-70.
24. Wimalawansa SJ. Significance of plasma PTH-rp in patients with hiper- calcemia of malignancy treated with bisphosphonate. Cancer 1994;73: 2223-30.
25. William SK, Robert JB, Gary JK. Oncologic Emergencies for the Inter- nist. Cleveland Clinic Journal of Medicine 2002, vol 69, No 3, 209-22. 26. Jeremy TSS, Owen PS. Haemato-
logical Emergencies Managing Hiper- calcemia in Adults and Children With Haematological Disorders. British Jour- nal of Haematology 2010;149:465-77. 27. LeGrand S, Leskuski D & Zama I.
Narrative Review: furosemide for hypercalcemia: an unproven yet com- mon practice. Annals of Internal Medi- cine 2008;149:259-63.
28. Body JJ. Hipercalcemia of malignancy. Semin Nephrol 2004;24(1):48-54. 29. Major P, Lortholary A, Hon J, et al. Zo-
ledronic acid is superior to pamidro- nate on the treatment of hipercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19(2)558-67.
30. Nussbaum SR, Younger J, Vandepol CJ, et al. Single-dose intravenous the-
rapy with pamidronate for the treatment of hypercalcemia of malignancy- :comparison of 30, 60, and 90 mg dosages. Am J Med 1993;95:297-304. 31. Saunders Y, Ross JR, Broadley KE,
Edmonds PM, Patel S, Steering Group. Systematic review of bisphosphonates for hypercalcaemia of malignancy. Pa- lliat Med 2004;18:418-31.
32. Fleisch H. Bisphosphonates: mecha- nisms of action. Endocr Rev 1998;19:80-100.
33. Berenson JR, Lipton A. Bisphosphona- tes in the treatment of malignant bone disease. Annu Rev Med 1999;50:237- 48.
34. Berenson JR. Treatment of hypercal- cemia of malignancy with bisphospho- nates. Semin Oncol 2002; 29:12.
35. Bilezikian JP. Management of acute hypercalcemia. New England Journal of Medicine 1992; 326:1196-203.
36. Leyland-Jones B. Treating cancer-re- lated hypercalcaemia with gallium nitrate. The Journal of Supportive On- cology 2004;2:509-16.
37. Warrell RP, Israel R, Frisone M, Snyder T, Gaynor JJ & Bockman RS. Gallium Nitrate for acute treatment of cancer- related hypercalcaemia. A ran-domized, double-blind comparison to calcitonin. Annals of Internal Medicine 1988;108:669-74.
38. Cvitkovic F, Armand JP, Tubiana-Hulin M, Rossi JF & Warrell RP Jr. Rando- mized, double-blind, phase II trial of gallium nitrate compared with pami- dronate for acute control of cancer related hypercalcemia. Cancer Journal 2006;12:47-53.
39. Ross JR et al. (2004) A systematic review of the role of bisphosphonates in metastatic disease. Health Technology Assessment 2004;8:1-176.
40. Camus C, Charasse C, Jouannic- Montier I, et al. Calcium free hemodia- lysis: experience in the treatment of 33
patients with severe hypercalcemia. Intensive Care Med 1996;22:116-21. 41. Koo WS, Jeon DS, Ahn SJ, Kim YS,
Yoon YS, Bang BK. Calcium-free hemodialysis for the management of hypercalcemia. Nephron 1996;72:424- 28.
42. Pecherstorfer, M, Brenner K & Zojer N. Current management strategies for hypercalcaemia. Treatments in Endocri- nology 2 (2003);273-92.
43. Silvia S, Dirk S. Metabolic Emergen- cies. Critical Reviews in Oncology/He- matology 58 (2006); 79-89.
44. Mitchel SC, Bertrand C, Alfred R, Ana Y. Recommendations for The Eva- luations of Risk and Prophylaxis of Tumor Lysis Syndrome (TLS) in Adults and Children With Malignant diseases: An Expert TLS Panel Consensus. Bri- tish Journal of Haematology 2010;149:578-86.
45. Coiffier B, Altman A, Pui CH, Younes A & Cairo MS. Guidelines for the mana- gement of pediatric and adult tumor lysis syndrome: an evidence-based re- view. Journal of Clinical Oncology 2008;26:2767-78.
46. Michallet AS, Tartas S. & Coiffier B. Optimizing management of tumor lysis syndrome in adults with hematologic malignancies. Supportive Cancer Therapy 2005;2:159-66.
47. Levine AM. Challenges in the management of Burkitt’s lymphoma. Clinical Lymphoma 3(Suppl. 1);2002:19-25.
48. Yim BT, Sims-McCallum RP & Chong PH. Rasburicase for the treatment and prevention of hyperuricemia. Annals of Pharmacotherapy 2003;37:1047-54. 49. Hsu HH, Chan YL & Huang CC. Acute
spontaneous tumor lysis presenting with hyperuricemic acute renal failure: clinical features and therapeutic appro- ach. Journal of Nephrology 2004;17:50- 56.
50. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high- grade non Hodgkin’s lymphoma. Am J
Med 1993;94:133-9.
51. Sallan S. Management of acute tumor lysis syndrome. Semin Oncol 2001;28:9-12.
52. Flombaum CD. Metabolic emergencies in the cancer patient. Semin Oncol 2000;27:322-34.
53. Altman A. Acute tumor lysis syndrome. Semin Oncol 2001;28:3-8. [30] Sallan S. Management of acute tumor lysis syndrome. Semin Oncol 2001;28:9-12. 54. Cairo MS, Bishop M. Tumour lysis
syndrome: new therapeutic strategies and classification. Br J Haematol 2004;127(1):3-11.
55. Berghmans T, Paesmans M, Body JJ. A prospective study on hyponatraemia in medical cancer patients: epidemiolo- gy, aetiology and differential diagnosis. Support Care Cancer 2000;8:192-7. 56. Nelson KA, Walsh D, Abdullah O, et al.
Common complications of advanced cancer. Semin Oncol 2000;27:34-44. 57. Ellison DH, Berl T. Clinical practice.
The syndrome of inappropriate antidiu- resis. N Eng J Med 2007;356(20):2064- 72.
58. Bressler RB, Houston DP. Water into- xication following moderate dose intra- venous cyclophosphamide. Arch intern med 1985;145(3):548-9.
59. Beck LH. Hypouricemia in the syndro- me of inappropriate secretion of anti- diuretic hormone. N Eng J Med 1979;301(10):528-30.
60. Laureno R, Karp BI. Myelinosis after correction of hiponatrémia. Ann Intern Med 1997;126(1):57-62.
61. Verbalis JG, Goldsmith SR, Greenberg A, et al. Hyponatremia treatment guide- lines 2007: expert panel recommenda- tions. Am J Med 2007;120(11 suppl 1):S1-21.
nant spinal cord compression in Ontario. Clin Oncol (R Coll Radiol) 2003;15:211-17.
63. Bach F, Larsen BH, Rohde K, et al. Metastatic spinal cord compression: occurrence, symptoms, clinical presen- tations and prognosis in 398 patients with spinal cord compression. Acta Neurochir (Wien) 1990;107:37-43. 64. Abraham JL, Banffy MB, Harris MB.
Spinal cord compression in patients with advanced metastatic cancer: ―all I care about is walking and living my life‖. JAMA 2008;299(8):937-46.
65. Helweg-Larsen S, Sorensen PS, Kreiner S. Prognostic factors in metas- tatic spinal cord compression: a pros- pective study using multivariate anal- ysis of variables influencing survi-val and gait function in 153 patients. Int J Radiat Oncol Biol Phys. 2000;46:1163- 69.
66. Kim RY, Spencer SA, Meredith RF, et al. Extradural spinal cord compression: analysis of factors determining function- nal prognosis—prospective study. Ra- diology 1990;176:279-82.
67. Rades D, Heidenreich F, Karstens JH. Final results of a prospective study of the prognostic value of the time to develop motor deficits before irradiation in metastatic spinal cord compression. Int J Radiat Oncol Biol Phys 2002;53:975-9.
68. Gilbert RW, Kim JH, Posner JB. Epidural spinal cord compression from metastatic tumour: diagnosis and treat- ment. Ann Neurol 1978;3:40-51.
69. Kwok Y, Tibbs PA, Patchell RA. Clinical approach to metastatic epidural spinal cord compression. Hematol Oncol Clin North Am 2006;20:1297-305.
70. Prasad D, Schiff D. Malignant spinal- cord compression. Lancet Oncol 2005;6:15-24.
71. Helweg-Larsen S, Sorensen PS. Symptoms and signs in metastatic spinal cord compression: a study of
progression from first symptom until diagnosis in 153 patients. Eur J Cancer. 1994;30A:396-8.
72. Schiff D, O’Neill BP, Suman VJ. Spinal epidural metastasis as the initial manifestation of malignancy: clinical features and diagnostic approach. Neurology 1997;49:452-6.
73. Schiff D. Spinal cord compression. Neurol Clin 2003;21(1):67-86.
74. Deyo Ra, Rainville J, Kent DL. What can the history and the physical exa- mination tell us about low back pain? JAMA 1992;268(6):760-5.
75. Makris A, Kunkler IH. The Barthel index in assessing the response to palliative radiotherapy in malignant spinal cord compression: a prospective audit. Clin Oncol 1995;7(2):82-6.
76. Helweg-Larsen S. Clinical outcome in metastatic spinal cord compression: a prospective study of 153 patients. Acta Neurol Scand 1996;94:269-75.
77. Cole JS, Patchel RA. Clinical approach to metastatic epidural spinal cord com- pression. Lancet Neurol 2008;7:459-66. 78. van der Sande JJ, Kroger R, Boogerd W. Multiple spinal epidural metastases: an unexpectedly frequent finding. J Neurol Neurosurg Psychiatry 1990;53:1001-3.
79. Schiff D, O’Neill BP, Wang CH, O’Fallon JR. Neuroimaging and treat- ment implications of patients with multiple epidural spinal metastases. Cancer 1998;83:1593-601.
80. White BD et al. Guidelines, Diagnosis and management of Patients at Risk of or with metastatic spinal cord compression: Summary of NICE Gui- dance. BMJ | 6 December 2008 | Vol 337.
81. Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical re- section in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 2005;366:643-8.
82. Ecker RD, Endo T, Wetjen NM, Krauss WE. Diagnosis and treatment of vertebral column metastases. Mayo Clin Proc. 2005;80:1177-86.
83. Klimo P Jr, Schmidt MH. Surgical management of spinal metastases. Oncologist 2004;9:188-96.
84. Posner JB, Chernik NL. Intracranial metastases from systemic cancer. Adv Neurol. 1978;19:579-92.
85. Tosoni A, Ermani M, Brandes AA. The pathogenesis and treatment of brain metastases: a comprehensive review. Crit Rev Oncol Hematol 2004;52:199- 215.
86. Peacock KH, Lesser GJ. Current therapeutic approaches in patients with brain metastases. Curr Treat Options Oncol 2006;7:479-89.
87. Klos KJ, O’Neill BP. Brain metastases. Neurologist 2004;10:31-46.
88. Kaal EC, Niel CG, Vecht CJ. Therapeutic management of brain metastasis. Lancet Neurol 2005;4:289- 98.
89. Lee ELT, Armstrong T. Increased intracranial pression. Clin J Oncol Nurs 2008;12(1):37-41.
90. Pierro G., Mark RG. Neurologic Com- plications of Cancer and its Treatment. Curr Oncol Rep (2010);12:50-59.
91. DeCamp MM Jr, Mentzer SJ, Swanson SJ, Sugarbaker DJ. Malignant effusive disease of the pleura and pericardium. Chest. 1997;112(4, suppl):291-95. 92. Spodick DH. Acute cardiac tamponade.
N Eng J Med 2003;349(7):684-90. 93. Reddy PS, Curtiss EI, O´Toole JD, et
al. Cardiac tamponade:hemodynamic observations in man. Circulation 1978;58(2):265-72.
94. Karam N, Patel P, deFilippi C. Diagnosis and management of chronic pericardial effusions. Am J Med Sci 2001;322:79-87.
95. Shabetai R. Pericardial and cardiac pressure. Circulation 1988;77(1):1-5.
96. Swami A, Spodick DH. Pulsus paradoxus in cardiac tamponade: a pathophysiologic continuum. Clin Cardiol 2003;26(5):215-7.
97. Tsang TS, Oh JK, Seward JB. Diagnosis and management of cardiac tamponade in the era of echocardiography. Clin Cardiol 1999;22:446-52.
98. Merce J, Sagrista –Sauleda J, Permanyer-Miralda G, et al. Should pericardial drainage be performed routinely in patients who have a large pericardial effusion without tamponade? Am J Med 1998;105(2):106-9.
99. Breen JF. Imaging of the pericardium. J Thorac Imaging 2001;16:47-54.
100. Shepherd FA. Malignant pericardial effusion. Curr Opin Oncol. 1997; 9:170- 174.
101. Moores DW, Dziuban SW Jr. Pericardial drainage procedures. Chest Surg Clin N Am 1995;5:359-73.
102. Maruyama R., Yokoyama H, Seto T et al. Catheter drainage followed by the instillation of bleomicin to manage malignant pericardial effusion in non- small cell lung cancer: a multiinstitutional fase II trial. J Thorac Oncol 2007;2(1):65- 8.
103. Morya T, Takigucci Y, Tabeta H, et al. controlling malignant pericardial by intrapericardial carboplatin administration in patients with primary non-small cell lung cancer. Br J Cancer 2000;83(7):858-62.
104. Kaira K, Takise A, Kobayashi G, et al. Management of malignat pericardial effusion with instillation of mitomycin C in non-small cell lung cancer.: Jpn J Clin Oncol 2005;35(2):57-60.
105. Vaitkus PT, Herrman HC, Lewinter MM. Treatment of malignant pericardial effusion. JAMA 1994;272(1):59-64. 106. Allen KB, Faber LP, Warren WH, et al.
Pericardial effusion: subxiphoide pericar- diostomy versus percutaneous catheter
drainage. Ann Thorac Surg 1999;67(2):437-40.
107. Georghiou GP, Stamler A, Sharoni E, et al. Video-assisted thoracoscopic pericar- dial window for diagnosis and mana- gement of pericardial effusions. Ann Thorac Surg 2005;80(2):607-10.
108. Bertrand M, Presant CA, Klein L, et al. Iatrogenic superior vena cava syndrome. A new entity. Câncer 1984;54(2):376-8. 109. Arinc S, Gonlugur U, Devran O, et al.
Prognostic factors in patients with small cell lung carcinoma. Med Oncol 2009. [Epub ahead of print].
110. Baker. G. & Barnes. H. Superior vena cava syndrome: Etiology, diagnosis, and treatment. American Journal of Critical Care 1992;1:54-64.
111. Uaje C. Kahsen K. & Parish L. Oncology emergencies. Critical Care Nursing Quarterly 1996;(4):26-34.
112. Yahalom J. Superior vena cava syndrome. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005:2273-80.
113. Wudel LJ Jr, Nesbitt JC. Superior vena cava syndrome. Curr Treat Options Oncol. 2001;2:77-91.
114. Parish JM, Marschke RF Jr, Dines DE, Lee RE. Etiologic considerations in su- perior vena cava syndrome. Mayo Clin Proc 1981;56:407-13.
115. Irene ES. Superior Vena Cava Syndrome: An oncologic Complication. Seminars in Oncology Nursing, Vol 12, No 4 (November);1996:312-17.
116. Mark LH, Jennifer AH; Treatment of on- cologic emergencies. Downloaded from the American Family Physician Web site at www.aafp.org/afp. Copyright © 2006 American Academy of Family physicians. 117. Qanadli SD, El Hajjam M, Bruckert F, et al. Helical CT phlebography of the supe- rior vena cava: diagnosis and evaluation of venous obstruction. AJR Am J Roentgenol 1999;172:1327-33.
118. Yellin A, Rosen A, Reichert N, Lieberman Y. Superior vena cava syn- drome: the myth-the facts. Am Rev Respir Dis 1990;141(5 pt 1):1114-8. 119. Nguyen NP, Borok TL, Welsh J, et al.
Safety and effectiveness of vascular endo prosthesis for malignant superior vena cava syndrome. Thorax 2009;64(2):174-8.
120. Lanciego C, Chacon JL, Julian A, et al. Stenting as first option for endovascular treatment fo malignant superior vena cava syndrome. AJR Am J Roentgenol 2001;177(3):585-93.
121. Urruticoechea A, Mesia R, Dominguez J, et al. Treatment of malignant superior vena cava syndrome by endovascular stent insertion: experience on 52 patients with lung cancer. Lung Cancer 2004;43:209-14.
122. Davenport D, Ferree C, Blake D, Raben M. Radiation therapy in the treatment of superior vena caval obstruction. Cancer 1978;42:2600-3.
123. Rowell NP, Gleeson FV. Steroids, ra- diotherapy, chemotherapy and stents for superior vena caval obstruction in car- cinoma of the bronchus: a systematic review. Clin Oncol (R Coll Radiol). 2002;14:338-51.
124. Mullen EC, Wang M. Recognizing hyperviscosity syndrome in patients with Waldenstrom macroglobulinemia. Clin J Oncol Nurs 2007;11(1):87-95.
125. Buxbaum J. Hyperviscosity syndrome in dysproteinemias. Am J Med Sci 1972;264:123-6.
126. Menke MN, feke GT, McMeel JW, et al. effect of plasmaferesis on hyperviscosity- related retinophaty and retinal hemody- namics in patients with Waldenstrom´s macroglobulinemia. Invest Ophtalmol Vis Sci2008;49(3):1157-60.
127. Kupas DF. Hyperviscosity syndrome. Accessed March 9, 2006 at: http://www.emedicine.com/emerg/topic75 6.htm.
128. Vitolo U, Ferreri A, Montoto S. Lymphoplasmacytic lymphoma-Waldens- trom´s macroglobulinemia. Crit Ver Oncol Hematol 2008;67:172-85.
129. Noppen M, Meysman M, D´HaeseJ, et al. Interventional Bronchoscopy: 5- year experience at the Academic Hospital of the Vrije Universiteit Brussell (AZ- VUB). Acta Clin Belg 1997;52(6):371-80.
130. Wood DE, Liu YH, Vallieres E, et al. Airway stenting for malignant and benign tracheobronchial stenosis. Ann Thorac Surg 2003;76(1):167-72 [discussion 173- 4].
131. Wood D. Airway stenting. Chest surg Clin N Am 2003;13(2):211-29.
132. Freitag L, Tekolf E, Steveling H, et al. Management of malignant esophagotra- cheal fistulas with airway stenting and
double stenting. Chest
1996;110(5):1155-60.
133. Lemaire A, Burfeind WR, Toloza E, et al. Outcomes of tracheobronchial stents in patients with malignant arway disease. Ann Thorac Surg 2005;80(2):434-7 [discussion:437-8].
134. Makris D, Marquette CH. Tracheo- bronchial stenting and central airway replacement. Curr Opin Pulm Med 2007;13(4):278-83.
135. Cavaliere S, venuta F, Foccoli P, et al. Endoscopic treatment of malignat airway obstruction in 2,008 patients. Chest 1996;110(6):1536-42.
136. Chella A, Ambrogi MC, Ribechini A, et al. Combined Nd:YAG laser /HDR bra- chytherapy versus Nd:YAG laser only in malignant central airway involvement: a prospective randomized study. Lung Cancer 2000;27(3):169-75.
137. Suh JH, Dass KK, Pagliaccio L, et al. Endobronchial radiation therapy with or without neodymium yttrium aluminum garnet laser resection for managing
malignant airway obstruction. Cancer 1994;73(10):2583-8.
138. Viscoli C. The evolution of the empirical management of fever and neutropenia in cancer patients. J Antimicrob Chemother 1998;41(suppl D):65-80.
139. Sipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer 2005;103:1103-13.
140. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis. 1999;29:490-4.
141. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51.
142. Heussel CP, Kauczor HU, Heussel GE, et al. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. J Clin Oncol 1999;17:796-805.
143. Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colonystimulating factors for chemotherapy-induced febrile neutropenia: a metaanalysis of rando- mized controlled trials. J Clin Oncol 2005;23:4198-214.
144. Markman M, Kennedy A, Webster K et al. Paclitaxel-associated hypersensitivity reactions: experience of the Gynecologic Oncology Program of the Cleveland Cli- nic Cancer Center. J Clin Oncol 2000;18:102-5.
145. Markman M, Zanotti K, Peterson G et al. Expanded experience with an intra- dermal skin test to predict for the pre- sence or absence of carboplatin hyper- sensitivity. J Clin Oncol 2003;21:4611-4.